Earnings Summary

Fulgent Genetics Inc’s revenue jumped 4.14% since last year same period to $70.51Mn in the Q4 2023. On a quarterly growth basis, Fulgent Genetics Inc has generated -16.75% fall in its revenue since last 3-months.

Fulgent Genetics Inc’s net profit fell -432.27% since last year same period to $-128.15Mn in the Q4 2023. On a quarterly growth basis, Fulgent Genetics Inc has generated -877.71% fall in its net profits since last 3-months.

Fulgent Genetics Inc’s net profit margin fell -411.12% since last year same period to -181.76% in the Q4 2023. On a quarterly growth basis, Fulgent Genetics Inc has generated -1074.38% fall in its net profit margins since last 3-months.

Fulgent Genetics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.32 - a -10.34% fall from last quarter’s estimates.

Fulgent Genetics Inc’s earning per share (EPS) estimates for the current year stand at -0.32.

Fulgent Genetics Inc’s earning per share (EPS) jumped 158.33% since last year same period to 0.28 in the Q4 2023. This indicates that the Fulgent Genetics Inc has generated 158.33% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Fulgent Genetics Inc’s return on assets (ROA) stands at -0.03.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Fulgent Genetics Inc’s return on equity (ROE) stands at -0.15.